Résumés
Résumé
Le syndrome lymphoprolifératif avec auto-immunité (ALPS, auto-immune lymphoproliferative syndrome) a été décrit il y a plus de 30 ans. Ce syndrome tumoral bénin, d’apparition précoce (en moyenne avant cinq ans), associe des adénopathies multifocales, une splénomégalie et, éventuellement, une hépatomégalie. Cette lymphoprolifération chronique s’accompagne d’une hypergammaglobulinémie, essentiellement G et A, et se caractérise par l’accumulation dans le sang et les organes lymphoïdes secondaires d’une population polyclonale de lymphocytes Tαβ matures n’exprimant ni CD4 ni CD8, appelés lymphocytes T « doubles négatifs » (LTαβ DN). Des manifestations auto-immunes sont retrouvées chez plus de deux tiers des patients ALPS, le plus souvent sous la forme de cytopénies auto-immunes (anémie hémolytique, thrombopénie et neutropénie). Des atteintes d’organes ou de systèmes (glomérulonéphrites, hépatites, uvéites, syndrome de Guillain-Barré) sont plus rarement observées. Cet article fait le point sur les défauts de la voie de signalisation Fas mis en évidence dans la genèse de l’ALPS.
Summary
Control of lymphocyte homeostasis is essential to ensure efficient immune responses and to prevent autoimmunity. Expansion followed by contraction of the lymphocyte pool are the basis of adaptive immune responses, and apoptosis is a crucial cellular modus operandi of the contraction phase. The death receptor Fas is a key player in lymphocyte apoptosis induction and patients lacking a functional Fas receptor develop a chronic lymphoproliferation termed autoimmune lymphoproliferative syndrome (ALPS). In rare instances, defects of the Fas signaling pathway have been associated with the ALPS condition. Although these defects with familial history are usually caused by inherited mutations of the corresponding genes, somatic mosaicism of these Fas mutations were also found in sporadic cases of ALPS. These findings might have important implications in deciphering the pathophysiological bases of other autoimmune diseases.
Parties annexes
Références
- 1. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr 1967 ; 70 : 891-9.
- 2. Rieux-Laucat F, Fischer A, Deist FL. Cell-death signaling and human disease. Curr Opin Immunol 2003 ; 15 : 325-31.
- 3. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes : genetic defects of apoptosis pathways. Cell Death Differ 2003 ; 10 : 124-33.
- 4. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 2005 ; 118 : 265-7.
- 5. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ 2003 ; 10 :26-35.
- 6. Nagata S, Suda T. Fas and Fas ligand : lpr and gld mutations. Immunol Today 1995 ; 16 : 39-43.
- 7. Pestano GA, Zhou Y, Trimble LA, et al. Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death. Science 1999 ; 284 : 1187-91.
- 8. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995 ; 268 : 1347-9.
- 9. Benkerrou M, Le Deist F, de Villartay J, et al. Correction of fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 1997 ; 27 : 2043-7.
- 10. Rieux-Laucat F, Blachere S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity : a possible genetic basis for dominant expression of the clinical manifestations. Blood 1999 ; 94 : 2575-82.
- 11. Vaishnaw AK, Orlinick JR, Chu JL, et al. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest 1999 ; 103 : 355-63.
- 12. Bleesing JJ, Brown MR, Straus SE, et al. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood 2001 ; 98 : 2466-73.
- 13. Drappa J, Vaishnaw AK, Sullivan KE, et al. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996 ; 335 : 1643-9.
- 14. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas : genotype influences penetrance. Am J Hum Genet 1999 ; 64 : 1002-14.
- 15. Morel L, Tian XH, Croker BP, Wakeland EK. Epistatic modifiers of autoimmunity in a murine model of lupus nephritis. Immunity 1999 ; 11 : 131-9.
- 16. Wang J, Zheng L, Lobito A, et al. Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 1999 ; 98 : 47-58.
- 17. Gronbaek K, Dalby T, Zeuthen J, et al. The V410I (G1228A) variant of the caspase-10 gene is a common polymorphism of the Danish population. Blood 2000 ; 95 : 2184-5.
- 18. Chun HJ, Zheng L, Ahmad M, et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002 ; 419 : 395-9.
- 19. Su H, Bidere N, Zheng L, et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005 ; 307 : 1465-8.
- 20. Salmena L, Lemmers B, Hakem A, et al. Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity. Genes Dev 2003 ; 17 : 883-95.
- 21. Holzelova E, Vonarbourg C, Stolzenberg MC, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med 2004 ; 351 : 1409-18.